Functional and anatomic changes in bilateral choroidal neovascularization associated with vitelliform macular dystrophy after intravitreal bevacizumab.

Abstract

PURPOSE:

We report the case of a young man with choroidal neovascularization (CNV) associated with vitelliform macular dystrophy (Best's disease), who underwent treatment with intravitreal bevacizumab.

CASE:

A 17-year-old white male presented for a routine ocular examination after reduction of visual acuity and was diagnosed with CNV in both eyes secondary to Best's disease. The diagnosis was confirmed by an ophthalmologic examination that included fluorescein angiography, indocyanine green angiography, Fourier optical coherence tomography, and microperimetry. Best corrected visual acuity was 5/10 in the right eye and 6/10 in the left eye. An intravitreal injection of bevacizumab was administered in both eyes.

RESULTS:

One month after bevacizumab injection, vision was 10/10 in both eyes. At a follow-up of 18 months, there was an absence of the neovascularization activity, and microperimetry revealed a marked improvement in retinal macular sensitivity.

CONCLUSION:

Intravitreal bevacizumab injection induced total regression of CNV as well as a morphologic and functional improvement in a young man affected by bilateral CNV secondary to Best's disease in a long-term follow-up.

• Authors: Gilda Cennamo, Ida Cesarano, Elisabetta Chiariello Vecchio, Michele Reibaldi, Giuseppe de Crecchio
• Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics (J Ocul Pharmacol Ther) Vol. 28 Issue 6 Pg. 643-6 (Dec 2012) ISSN: 1557-7732 [Electronic] United States
• PMID: 22742532 (Publication Type: Case Reports, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Bevacizumab

Topics

• Adolescent
• Angiogenesis Inhibitors (administration & dosage, therapeutic use)
• Antibodies, Monoclonal, Humanized (administration & dosage, therapeutic use)
• Bevacizumab
• Choroidal Neovascularization (drug therapy, etiology)
• Fluorescein Angiography
• Follow-Up Studies
• Humans
• Intravitreal Injections
• Male
• Tomography, Optical Coherence
• Treatment Outcome
• Visual Acuity (drug effects)
• Vitelliform Macular Dystrophy (drug therapy, physiopathology)